ArticleRheumatology (Oxford, England)2026
Early mepolizumab initiation during remission induction is associated with lower organ damage burden in EGPA: a multicentre cohort study.
Article in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective of this study was to evaluate whether early mepolizumab initiation during remission induction is associated with favourable clinical outcomes and lower organ damage burden in patients with eosinophilic granulomatosis with polyangiitis (EGPA).
methodsThis retrospective multicentre cohort study used data from the Kyushu Vasculitis Cohort Study. Patients with EGPA were classified into an early mepolizumab group, in which mepolizumab was initiated within 3 months of remission induction, and a conventional group. The primary end point was clinical remission at 1 year, defined as BVAS = 0 with prednisolone ≤4 mg/day. Secondary end points included remission at 6 months and 2 years, glucocorticoid exposure, relapse, mortality, and organ damage as assessed by the Vasculitis Damage Index (VDI). Longitudinal VDI values from 6 months to 2 years were analysed using a linear mixed-effects model.
resultsSixty-four patients were included (early mepolizumab, n = 16; conventional, n = 48). Clinical remission at 1 year was achieved more frequently in the early mepolizumab group than in the conventional group (69% vs 27%; P = 0.006). At 2 years, remission was achieved in 10/10 (100%) vs 13/45 (29%) evaluable patients (P < 0.001), and glucocorticoid discontinuation was achieved in 4/10 (40%) vs 4/45 (9%) of those patients (P = 0.029). BVAS decreased markedly in both groups. Early mepolizumab initiation was associated with lower longitudinal VDI values (β = -0.36, 95% CI -0.70 to -0.03; P = 0.032).
conclusionEarly mepolizumab initiation was associated with higher remission rates, lower glucocorticoid exposure and lower organ damage burden during the first 2 years in EGPA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.